Search Medical Condition
Please enter condition
Please choose location from dropdown

Bilbao, Basurto Clinical Trials

A listing of Bilbao, Basurto clinical trials actively recruiting patients volunteers.


Found (67) clinical trials

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II IIIA or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

This is a randomized, double-blinded study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in patients with resectable Stage II, IIIA, or select IIIB nonsmall cell lung cancer (NSCLC) followed by open-label adjuvant atezolizumab or best supportive care ...


Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib Previously Treated With 2 or More TKIs

The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs with BCR-ABL ratios 1% IS at screening.


A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

This is a single-arm, multi-center, open-label extension study designed to provide pertuzumab to patients who continue to derive benefit from pertuzumab, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored Global study who continue ...


A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

This is a non-interventional, multicenter, prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with mCRPC, based on documented metastatic prostate cancer and documented castration resistance. Castrate-resistant prostate cancer is defined by disease progression despite testosterone <50 ng/dL, and/or androgen deprivation therapy, and/or a history ...

Phase N/A

Thoracic Tumours Register

In Europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. Potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. However, the priorities should be ...

Phase N/A

Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

The FOREST study is a phase 3, randomised, controlled, multicentric, open-label clinical trial to prove the noninferiority of fosfomycin versus meropenem in the targeted treatment of bacteraemic UTI due to ESBL-EC, designed as a real practice trial. It is a non-commercial, investigator-driven clinical study funded through a public competitive call ...


This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain

The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.

Phase N/A

COPD Readmissions Prediction- ReCOPD Project

DESIGN: A prospective observational cohort study with a nested case control study, with one year follow-up from index hospital admission. SETTING: Multicenter and multidisciplinary study taking part the following hospitals: Costa del Sol Hospital (Andalusia), Nuestra Seora de la Candelaria University Hospital (Canary Islands), Gregorio Maran General University Hospital (Madrid), ...

Phase N/A

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 ...